Phase I/II Trial of Repeat Dosing of Super-Selective Intraarterial Infusion of Erbitux (Cetuximab) and Avastin (Bevacizumab) for Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age

This study assesses the safety and efficacy of repeat monthly dosing of super-selective intra-arterial cerebral infusion (SIACI) of cetuximab and bevacizumab in patients < 22 years of age.

Start Date01 Nov 2025

Sponsor / Collaborator

University of Miami

NCT06867822

/ Not yet recruitingPhase 1/2IIT

A Phase I/Ib Trial of ProAgio, an Anti-avb3 Integrin Cytotoxin, in Combination with 5-fluorouracil , Irinotecan and Bevacizumab for Advanced/metastatic Colorectal Cancer (ProAgio in CRC)

This is an open-label Phase I/Ib dose-escalation, dose-expansion clinical trial of the safety, pharmacokinetics and clinical activity of ProAgio combined with 5-fluorouracil, irinotecan (FOLFIRI) and bevacizumab for untreated advanced/metastatic CRC. The study will use an Accelerated titration BOIN design in Phase I to determine the recommended RP2D of ProAgio with FOLFIRI + bevacizumab. The trial will estimate the RP2D of ProAgio when combined with FOLFIRI + bevacizumab, starting from 2 dose levels lower than the estimated RP2D of ProAgio alone. Accelerated titration BOIN design will enroll patients with the 4 combination dose levels.
Subjects will be selected based on following criteria: previously untreated advanced/metastatic CRC, ECOG performance status (0-1), and adequate organ functions. Subjects with recent surgeries, history of recent thromboembolic events or significant cardiovascular disease will be excluded.
Once the MTD and RP2D of ProAgio with FOLFIRI have been identified, an expansion cohort of 12 subjects with advanced/metastatic CRC will begin. The purpose of the expansion cohort is to confirm the safety of the regimen and provide preliminary data on the activity of ProAgio + FOLFIRI + bevacizumab.

Start Date01 Jun 2025

Sponsor / Collaborator

The University of Alabama at Birmingham

[+1]

NCT06393751

/ Not yet recruitingPhase 1/2IIT

A Randomized Phase 1/2 Trial Evaluating the Addition of Tolinapant to Weekly Paclitaxel With or Without Bevacizumab in Patients With Recurrent Epithelial Ovarian Cancer

This phase I/II trial tests the safety, best dose and effectiveness of adding tolinapant (ASTX660) to paclitaxel with or without bevacizumab in treating patients with ovarian cancer that has come back after a period of improvement (recurrent). Tolinapant may stop the growth of tumor cells by blocking proteins, such as XIAP and cIAP1, that promote the growth of tumor cells and increase resistance to chemotherapy. Paclitaxel is in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to the tumor. This may slow the growth and spread of tumor cells. Adding ASTX660 to paclitaxel with or without bevacizumab may be safe, tolerable and/or effective in treating patients with recurrent ovarian cancer.

Start Date02 May 2025

Sponsor / Collaborator

National Cancer Institute

100 Clinical Results associated with Bevacizumab

100 Translational Medicine associated with Bevacizumab

100 Patents (Medical) associated with Bevacizumab

22,711

Literatures (Medical) associated with Bevacizumab

01 Dec 2025·Journal of Gastrointestinal Cancer

Third- or Further-Line Treatment in Patients with MSS Type Metastatic Colorectal Cancer

Article

Author: Gou, Miaomiao ; Qian, Niansong ; Dai, Guanghai ; Zhang, Yong ; Wang, Zhikuan

BACKGROUND:

The survival benefit from later-line treatment for patients with metastatic colorectal cancer (mCRC) remains disappointing. Here, in a real-world study, we were aimed to evaluate which choice will affect the survival of mCRC patients after standard treatment in Chinese patients.

METHODS:

A total of 129 patients with refractory mCRC were involved in the study. They received targeted monotherapy or combined with chemo-agents or PD-1 inhibitor before death. Overall survival (OS) and progression-free survival (PFS) were reviewed and evaluated from clinical features and treatment options.

RESULTS:

Among the 129 patients, the median age was 56 years (25-81). The mOS from third-line was 12.5 months. OS of patients who treated with chemo plus targeted therapy group in third-line was shown to be superior to pd-1 inhibitor in combination with antiangiogenic agents or antiangiogenic monotherapy group (15.6 m vs. 10.5 m vs. 8.4 m, p < 0.05). Patients had received triplet-drugs (bevacizumab plus low-dose irinotecan and oxaliplatin) and had prolonged survival compared to those had not (21.3 m vs 10.3 m, p = 0.004). OS between patients who had immunotherapy history or not was not significantly different (p > 0.05). The mPFS was 3.5 months in patients who had administered with antiangiogenic targeted agents plus anti-pd-1 and 4.7 months in chemo plus targeted therapy group and 2.2 months in the other group. In the triplet drugs group, preliminary results showed that ORR was 13.3% and DCR was 80%. The median PFS was 5.1 m, and the median OS was 10.6 m.

CONCLUSIONS:

Triplet drugs resulted in significantly longer overall survival, and immunotherapy may have limited benefit in MSS type CRC patients.

01 Apr 2025·PROGRESS IN NEUROBIOLOGY

Single-cell RNA sequencing reveals ECM remodeling-tumor stiffness-FAK as a key driver of vestibular schwannoma progression

Article

Author: Long, Jianfei ; Xu, Jian ; Zhang, Yu ; Wang, Bin ; Zhong, Ping

Vestibular schwannoma (VS), characterized by the absence of merlin expression, is the most prevalent benign tumor located at the cerebellopontine angle, lacking approved pharmaceutical interventions except for off-label utilization of bevacizumab. The role of Tumor stiffness-Focal adhesion kinase (FAK) activation in fueling tumor progression is well-established, with merlin deficiency serving as a biomarker for tumor sensitivity to FAK inhibitors. In this context, we investigated whether Tumor stiffness-FAK contributes to VS progression. Single-cell RNA sequencing revealed associations between VS progression and gene sets related to "Response to mechanical stimulus" and "Neurotrophin signaling pathway". Histological studies indicated a potential involvement of neurotrophins in early stages of VS tumorigenesis, while enhanced Extracellular matrix (ECM) remodeling-Tumor stiffness-FAK signaling accompanies later stages of VS progression. In vitro experiments demonstrated that elevated matrix stiffness induces cytoskeletal remodeling, cell proliferation, and metalloproteinase expression in VS cells by activating FAK. Conversely, FAK inhibition diminishes these effects. Collectively, this study suggests that ECM remodeling-Tumor stiffness contributes to VS progression via FAK activation, positioning FAK as a promising therapeutic target in treating VS.

01 Apr 2025·ANNALS OF SURGICAL ONCOLOGY

Posterior Hepatectomy and Inferior Vena Cava Graft Reconstruction for En Bloc Resection of a Hepatocellular Carcinoma: A Tribute to Couinaud’s Liver Anatomy Description

Article

Author: Tzedakis, Stylianos ; Jeddou, Heithem ; Livin, Marie ; Robin, Fabien ; Le Floc'h, Bastien ; Boudjema, Karim

Abstract:

Background:

Hepatocellular carcinoma (HCC) associated with major vasculature tumor extension is considered an advanced stage of disease to which palliative radiotherapy or chemotherapy is proposed.1,2 Surgical resection associated with chemotherapy or chemoembolization could be an opportunity to improve overall survival and recurrence-free survival in selected cases in a high-volume hepatobiliary center.3,4 Moreover, it has been 25 years since Couinaud described the entity of a posterior liver located behind an axial plane crossing the portal bifurcation.5 The aim of this video was to show how to reproduce such a resection technique.

Methods:

We report the case of a 72-year-old male presenting with a 6 cm HCC developed in a well-compensated Child–Pugh A alcohol-related cirrhosis and localized in the dorsal liver sector. The tumor invaded the retrohepatic inferior vena cava (IVC) as well as segment 2 and the right posterior section glissonean pedicles. The initial management of the patient was performed outside of a reference center for hepatobiliary surgery and the tumor was initially considered unresectable. Transarterial chemoembolization was judged ineffective due to the size and location of the tumor. Initial treatment included 6 months of atezolizumab–bevacizumab, permitting tumor volume stability and enabling surgical resection.

Results:

The procedure included an en bloc posterior hepatectomy (H1267)6 with IVC resection and polytetrafluoroethylene (PTFE) graft replacement. A well-tolerated intermittent pedicle and IVC clamping of 30 min in total was used. The duration of surgery was 240 min, with 30 min of total vascular liver exclusion, and total blood loss was 650 mL. The patient was discharged on postoperative day 8. R0 resection was achieved and the patient was free of disease at 1 year post-surgery.

Conclusion:

To our knowledge, this video reports the first posterior hepatectomy performed in clinical practice and demonstrates liver anatomy as described by Couinaud in 1999.5 Moreover, complex vascular resections for HCC should be considered a valid therapeutic option in selected cases and high-volume hepatobiliary centers.

1,139

News (Medical) associated with Bevacizumab

24 Mar 2025

·pipelinereview.com

Junshi Biosciences Announces Approval of sNDA for Toripalimab in Combination with Bevacizumab for 1st-line Treatment of Advanced Hepatocellular Carcinoma

SHANGHAI, China I March 23, 2025 I Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the National Medical Products Administration (“NMPA”) has approved the supplemental new drug application (“sNDA”) for the company’s product, toripalimab, in combination with bevacizumab for the first-line treatment of unresectable or metastatic hepatocellular carcinoma (“HCC”) patients. Globally, liver cancer is a common malignant tumor of the digestive system, and the main pathological type is HCC (accounting for about 90%). According to data released by the GLOBOCAN for 2022, the annual number of new cases and deaths of liver cancer worldwide was 866,000 and 759,000, respectively. China has a high incidence of liver cancer. In 2022, the number of new liver cancer cases reached 368,000 (accounting for 42.4% of global cases), ranking fourth among domestic malignant tumors, with 317,000 deaths (accounting for 41.7% of global cases), ranking second among domestic malignant tumors. Due to its insidious onset, about 70%-80% of liver cancer patients in China are already at the intermediate or advanced stage at first diagnosis, with a median overall survival (“OS”) of only approximately 10 months and a five-year survival rate of approximately 12%. The supplemental NDA approval is based on data from the HEPATORCH study (NCT04723004), which is a multinational multi-center, randomized, open-label, active-controlled phase 3 clinical study. Professor Jia FAN, an academician of the Chinese Academy of Sciences, from Zhongshan Hospital affiliated to Fudan University, served as the principal investigator. HEPATORCH was launched in 57 clinical centers in the Chinese mainland, China’s Taiwan and Singapore, and a total of 326 patients were enrolled. The study aimed to evaluate the efficacy and safety of toripalimab in combination with bevacizumab for the first-line treatment of unresectable or metastatic HCC compared to the standard treatment with sorafenib. In September 2024, the results of the HEPATORCH study made its debut at the 27 th National Clinical Oncology Conference and 2024 Chinese Society of Clinical Oncology (CSCO) Academic Annual Meeting. The results of the study showed that the primary endpoints, progression-free survival (“PFS,” based on independent radiographic review) and OS, both achieved positive results. HEPATORCH demonstrated that compared with sorafenib, toripalimab in combination with bevacizumab could significantly extend the PFS and OS of patients, with a median PFS of 5.8 months vs. 4.0 months, reduce the risk of disease progression or death by 31% (hazard ratio [HR]=0.69, 95% CI: 0.525-0.913; P=0.0086), with a median OS of 20.0 months vs. 14.5 months, and reduce the risk of death by 24% (HR=0.76, 95% CI: 0.579-0.987; P=0.0394). The objective response rate (“ORR”) of the toripalimab and bevacizumab group was significantly higher than that of the sorafenib group. The ORR of the two groups were 25.3% and 6.1%, respectively. Furthermore, the combination therapy has a good safety profile in patients with advanced HCC. The toxicity spectrum is consistent with the known toxicity spectrum of the standard monotherapy, and no new safety signal was identified. Academician Jia FAN from Zhongshan Hospital affiliated with Fudan University said, “The combination of immunotherapy and anti-angiogenic therapy has become the foundation of first-line treatment for advanced liver cancer. The HEPATORCH study has fully demonstrated the clinical efficacy of toripalimab in liver cancer patients in China, achieving an ORR of 25.3%, a median PFS of 5.8 months, and a median OS of 20.0 months. The ‘TB’ regimen combining toripalimab with bevacizumab will benefit many advanced liver cancer patients in China.” Dr. Jianjun ZOU, Junshi Biosciences’ General Manager and CEO said, “Building on the success of our previously approved 10 indications—the ‘Perfect 10,’ toripalimab has reached another breakthrough achievement with the official approval of its 11 th indication, and we are extremely elated! China has suffered the brunt of liver cancer, and Chinese patients have long faced the challenge of limited treatment options. Junshi Biosciences consistently prioritizes the clinical needs of liver cancer treatment around the world, advancing clinical research through combination strategies tailored to patients across the different stages of disease progression. Our goal is to provide more precise and diverse treatment options for liver cancer patients. Moving forward, we remain dedicated to liver cancer innovation and integrating even greater ‘Chinese Wisdom’ into the fight against this disease.” About Toripalimab Toripalimab is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, and to induce PD-1 receptor internalization (endocytosis function). Blocking PD-1 interactions with PD-L1 and PD-L2 promotes the immune system’s ability to attack and kill tumor cells. More than forty company-sponsored toripalimab clinical studies covering more than fifteen indications have been conducted globally by Junshi Biosciences, including in China, the United States, Europe and Southeast Asia. Ongoing or completed pivotal clinical trials evaluating the safety and efficacy of toripalimab cover a broad range of tumor types, including cancers of the lung, nasopharynx, esophagus, stomach, bladder, breast, liver, kidney, and skin. In the Chinese mainland, toripalimab was the first domestic anti-PD-1 monoclonal antibody approved for marketing (approved in China as TUOYI ® ). Currently, there are eleven approved indications for toripalimab in the Chinese mainland: The first 10 indications have been included in the National Reimbursement Drug List (NRDL) (2024 Edition). Toripalimab is the only anti-PD-1 monoclonal antibody included in the NRDL for the treatment of melanoma, perioperative treatment of NSCLC, treatment of RCC and treatment of TNBC. In October 2024, toripalimab for the treatment of recurrent or metastatic NPC was approved in Hong Kong SAR, China. Internationally, toripalimab has been approved for marketing in the United States, the European Union, India, the UK, Jordan, Australia and other countries and regions. In addition, toripalimab BLAs are under reviews in many countries or regions around the global. About Junshi Biosciences Founded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapeutics. The company has established a diversified R&D pipeline comprising over 50 drug candidates, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Five of the company’s products have received approvals in China and international markets, one of which is toripalimab, China’s first domestically produced and independently developed anti-PD-1 monoclonal antibody. Toripalimab has been approved in over 35 countries and regions including China, the US, and Europe. During the COVID-19 pandemic, Junshi Biosciences actively shouldered the social responsibilities of a Chinese pharmaceutical company through its involvement in developing etesevimab, MINDEWEI ® , and other novel therapies for the prevention and treatment of COVID-19. With a mission of “providing patients with world-class, trustworthy, affordable, and innovative drugs,” Junshi Biosciences is “In China, For Global.” At present, the company boasts approximately 2,500 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing, Guangzhou, etc.). For more information, please visit: http://www.junshipharma.com. SOURCE: Junshi Biosciences

Clinical ResultDrug ApprovalPhase 3NDACSCO

21 Mar 2025

·www.prnewswire.com

Akeso's Cadonilimab Combined with Concurrent Chemoradiotherapy Demonstrates Promising Efficacy in Locally Advanced Cervical Cancer: Data Published at the 2025 SGO Annual Meeting

HONG KONG, March 20, 2025 /PRNewswire/ -- Akeso Inc. (9926.HK) presented promising phase III safety run-in results from the COMPASSION-18/AK104-305 study, at the 2025 Annual Meeting of the Society of Gynecologic Oncology (SGO). The study evaluates the global first-in-class PD-1/CTLA-4 bispecific antibody, cadonilimab (AK104), in combination with concurrent chemoradiotherapy (CCRT) for the treatment of locally advanced cervical cancer. Currently, CCRT is the standard of care for locally advanced cervical cancer, but approximately 30%-40% of patients experience relapse or disease progression within five years. Cadonilimab, with its unique dual-target mechanism, is designed to simultaneously inhibit the PD-1 and CTLA-4 immune checkpoint pathways. It has received approval from the National Medical Products Administration (NMPA) in China for use in patients with recurrent or metastatic cervical cancer who have failed prior platinum-based chemotherapy. The Phase III COMPASSION-16 study further confirmed that cadonilimab, when combined with platinum-based chemotherapy (with or without bevacizumab), significantly improves progression-free survival (PFS) and overall survival (OS) in patients with persistent, recurrent, or metastatic cervical cancer. Based on these compelling results, the supplemental New Drug Application (sNDA) for cadonilimab as a first-line treatment for persistent, recurrent, or metastatic cervical cancer is currently under regulatory review. At this year's SGO, data from the COMPASSION-18 study highlighted the exceptional efficacy seen in patients receiving cadonilimab in combination with CCRT during the safety run-in phase. The results demonstrate the considerable therapeutic potential of cadonilimab combined with CCRT for locally advanced cervical cancer. The study included a more challenging patient cohort, with a notably higher proportion of patients having PD-L1 CPS <1 (38.2%) and an ECOG performance status of 1 (52.9%) compared to other similar studies. Overall Response Rate (ORR): The evaluable patients achieved a remarkable ORR of 100%, with a complete response (CR) rate of 84.8% and a partial response (PR) rate of 15.2%, which significantly outperformed data from other comparable studies. The median duration of response (DoR) has yet to be reached. Progression-Free Survival (PFS): While the median PFS has not been reached, the 12-month PFS rate was 74.9%. Subgroup Analysis: Patients with PD-L1 CPS ≥1, ECOG 0, and those not infected with COVID-19 derived even greater benefit from the treatment, with 12-month PFS rates of 85%, 87.5%, and 81.3%, respectively. Safety Profile: Cadonilimab combined with CCRT exhibited a favorable safety profile, demonstrating good tolerability and manageable adverse events. Notably, there were no treatment-related deaths (TRAE) and no new safety concerns were identified. Cadonilimab is making significant progress in treating both recurrent/metastatic and locally advanced cervical cancer, establishing a comprehensive therapeutic approach. The positive results from the COMPASSION-18 study reinforce its potential in a broader patient population. As clinical development continues, cadonilimab is set to redefine cervical cancer treatment, offering long-term survival benefits to more patients. SOURCE Akeso, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical ResultPhase 3Drug ApprovalASCOImmunotherapy

18 Mar 2025

·pipelinereview.com

Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer

COPENHAGEN, Denmark I March 17, 2025 I Genmab A/S (Nasdaq: GMAB) announced today updated data from cohort B1 of the Phase 1/2 RAINFOL-01 study of rinatabart sesutecan (Rina-S ® ), an investigational folate receptor-alpha (FRα)-targeted, TOPO1 antibody-drug conjugate (ADC) that showed Rina-S 120 mg/m 2 every 3 weeks (Q3W) resulted in a confirmed objective response rate (ORR) of 55.6% (95% CI: 30.8-78.5) in heavily pre-treated ovarian cancer (OC) patients regardless of FRα expression levels. With a median on-study follow-up of 48 weeks, 1 out of 10 patients experienced disease progression and the median duration of response (mDOR) was not reached (95% CI: 40.14-NR). The data are from the dose expansion cohort of the multi-part study evaluating the safety and efficacy of Rina-S as a single agent in solid tumors that are known to express FRα and were presented at the 2025 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer ® (SGO) in Seattle, Washington. “The antitumor activity observed in the dose expansion cohort continues to demonstrate the potential for a much-needed treatment option for patients with PROC, who have historically had poor prognosis. I am hopeful that further exploration of Rina-Swill lead to advancements in the treatment landscape.” said Elizabeth Lee, M.D., a medical oncologist in the gynecologic oncology program at Dana-Farber. The B1 cohort is a dose expansion study in patients with histologically or cytologically confirmed advanced OC (epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer). Rina-S 120 mg/m 2 Q3W at a median on-study follow-up of 48 weeks showed encouraging antitumor activity; the confirmed ORR was 55.6% (95% CI: 30.8-78.5), the disease control rate (DCR) was 88.9% (95% CI: 65.3-98.6), and the median duration of response (mDOR) was not reached (95% CI: 40.14-NR). In the 18 patients evaluable for response treated with 120 mg/m 2 Q3W, complete responses were observed in 4 patients (2 confirmed; 2 unconfirmed) and 8 patients experienced confirmed partial responses (44.4%). Most responses with Rina-S 120 mg/m 2 were observed early (at week 6). Only one patient in the 120 mg/m 2 treatment arm was not evaluable. In the Rina-S 100 mg/m 2 Q3W treatment arm (N=22), at a median on study follow-up of 46 weeks, the confirmed ORR was 22.7% (95% CI: 7.8-45.4), the DCR was 86.4% (95% CI: 65.1-97.1), and the mDOR was not reached (95% CI, 16.3-NR). Partial responses were observed in 4 patients (18.2%) and 1 patient (4.5%) experienced a complete response. Rina-S 120 mg/m 2 has been selected for further evaluation in the RAINFOL-01 and Phase 3 RAINFOL-02 trials for patients with platinum resistant ovarian cancer (PROC). In this Phase 1/2 study, common treatment-emergent adverse events (TEAEs) included anemia, nausea, neutropenia, leukopenia, fatigue, thrombocytopenia, vomiting, diarrhea, alopecia, and hypokalemia. Dose reductions and treatment discontinuations were infrequent and no new safety signals were observed. “The updated results reinforce the potential of Rina-S and further validate our development approach in advanced ovarian cancer,” said Judith Klimovsky, M.D., Executive Vice President and Chief Development Officer of Genmab. “We are excited to keep moving forward with the ongoing Phase 3 trial, to evaluate the potential of Rina-S as a treatment option for patients facing this challenging disease.” The safety and efficacy of rinatabart sesutecan has not been established for these investigational uses. About the RAINFOL TM -01 Trial RAINFOL-01 ( NCT05579366 ) is an open-label, multicenter Phase 1/2 study, designed to evaluate the safety and efficacy of rinatabart sesutecan (Rina-S) as a single agent Q3W at various doses in solid tumors that are known to express FRα. The study consists of multiple parts including Part A dose-escalation cohorts; Part B tumor-specific monotherapy dose-expansion cohorts; Part C platinum-resistant ovarian cancer (PROC) cohort; and Part D combination therapy cohorts. Part B of the trial includes the B1 cohort, a dose expansion study in patients with histologically or cytologically confirmed advanced OC (epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer). Patients were randomized 1:1 to 100 mg/m 2 and 120 mg/m 2 dose cohorts. Median age was 62.5 and 64.5 years in the 100 mg/m 2 and 120 mg/m 2 cohorts, respectively. Study participants were previously treated with a median of 3 prior lines of therapy (range 1-4). Patients received prior treatment with bevacizumab (90.9% in the 100 mg/m 2 group and 90.0% in the 120 mg/m 2 group respectively), PARP inhibitors (68.2%; 65%), and mirvetuximab soravtansin (18.2%; 19%). Initial results from Part B of this trial were presented during a mini-oral session at the European Society of Medical Oncology Congress 2024 (ESMO). About Ovarian Cancer Ovarian cancer is a major global health issue, with over 320,000 new cases diagnosed annually worldwide. i It ranks as the eighth most common cancer and the eighth leading cause of cancer-related deaths among women globally. ii The disease is often diagnosed at an advanced stage due to its subtle and non-specific symptoms, such as abdominal bloating, pelvic pain and difficulty eating. iii Standard of care for platinum resistant ovarian cancer typically involves single agent chemotherapy (pegylated liposomal doxorubicin (PLD), topotecan, gemcitabine or paclitaxel). iv Approximately 70-90% of women with advanced-stage ovarian cancer worldwide experience a recurrence after initial treatment. v Ovarian cancer has a low five-year survival rate, which varies significantly by region, but generally hovers around 30-50%. vi,vii About Rinatabart Sesutecan (Rina-S ® ; GEN1184) Rinatabart sesutecan (Rina-S; GEN1184) is a FRα-targeted, TOPO1 ADC, currently being evaluated for the potential treatment of ovarian cancer and other FRα-expressing cancers. A Phase 3 trial (RAINFOL-02, NCT06619236 ) evaluating Rina-S in patients with platinum resistant ovarian cancer compared to treatment of investigator’s choice is ongoing. In January 2024, the U.S. Food and Drug Administration granted Fast Track designation to Rina-S for the treatment of patients with FRα-expressing high-grade serous or endometrioid platinum-resistant ovarian cancer. Please visit www.clinicaltrials.gov for more information. About Genmab Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving the lives of patients with innovative and differentiated antibody therapeutics. For more than 25 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational, quantitative and data sciences, resulting in a proprietary pipeline including bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators and effector function-enhanced antibodies. By 2030, Genmab’s vision is to transform the lives of people with cancer and other serious diseases with knock-your-socks-off (KYSO) antibody medicines ® . Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com and follow us on LinkedIn and X . i World Cancer Research Fund International. https://www.wcrf.org/cancer-trends/ovarian-cancer-statistics/ . Accessed August 2024. ii World Ovarian Cancer Coalition. https://worldovariancancercoalition.org/about-ovarian-cancer/key-stats/ . Accessed August 2024. iii Dilley, James et al. Ovarian cancer symptoms, routes to diagnosis and survival – Population cohort study in the ‘no screen’ arm of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Gynecologic oncology vol. 158,2 (2020): 316-322. doi:10.1016/j.ygyno.2020.05.002. iv Eskander RN, Moore KN, Monk BJ, Herzog TJ, Annunziata CM, O’Malley DM and Coleman RL (2023) Overcoming the challenges of drug development in platinum-resistant ovarian cancer. Front. Oncol. 13:1258228 Ovarian Cancer Research Alliance. https://ocrahope.org/patients/diagnosis-and-treatment/recurrence/ . v Ovarian Cancer Research Alliance. https://ocrahope.org/patients/diagnosis-and-treatment/recurrence/ . vi European Institute of Women’s Health. https://eurohealth.ie/policy‐brief‐women‐and‐ovarian‐cancer‐in‐the‐eu‐2018/ . Accessed August 2024. vii American Cancer Society. Stages of Ovarian Cancer. https://www.cancer.org/cancer/types/ovarian-cancer/detection-diagnosis-staging/survival-rates.html. Accessed August 2024 . SOURCE: Genmab

Clinical ResultPhase 3ASCOFast Track

100 Deals associated with Bevacizumab

External Link

KEGG	Wiki	ATC	Drug Bank
D06409	Bevacizumab	L01XC07	DB00112

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Unresectable Hepatocellular Carcinoma	Japan	Chugai Pharmaceutical Co., Ltd.	25 Sep 2020
Hepatocellular Carcinoma	United States	Genentech, Inc.	29 May 2020
Recurrent Glioblastoma	United States	Genentech, Inc.	29 May 2020
Recurrent Primary Peritoneal Carcinoma	United States	Genentech, Inc.	14 Nov 2014
Ovarian Cancer	Japan	Chugai Pharmaceutical Co., Ltd.	22 Nov 2013
Glioma	Japan	Chugai Pharmaceutical Co., Ltd.	14 Jun 2013
Breast Cancer	Japan	Chugai Pharmaceutical Co., Ltd.	26 Sep 2011
Colorectal Cancer	Japan	Chugai Pharmaceutical Co., Ltd.	18 Sep 2009
Metastatic Renal Cell Carcinoma	United States	Genentech, Inc.	31 Jul 2009
Glioblastoma	United States	Genentech, Inc.	05 May 2009
Metastatic Colorectal Carcinoma	United States	Genentech, Inc.	05 May 2009
Ganglioglioma	Japan	Chugai Pharmaceutical Co., Ltd.	18 Apr 2007
Non-squamous non-small cell lung cancer	United States	Genentech, Inc.	11 Oct 2006
Fallopian Tube Carcinoma	European Union	Roche Registration GmbH	12 Jan 2005
Fallopian Tube Carcinoma	Iceland	Roche Registration GmbH	12 Jan 2005
Fallopian Tube Carcinoma	Liechtenstein	Roche Registration GmbH	12 Jan 2005
Fallopian Tube Carcinoma	Norway	Roche Registration GmbH	12 Jan 2005
Metastatic breast cancer	European Union	Roche Registration GmbH	12 Jan 2005
Metastatic breast cancer	Iceland	Roche Registration GmbH	12 Jan 2005
Metastatic breast cancer	Liechtenstein	Roche Registration GmbH	12 Jan 2005

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced Head and Neck Carcinoma	Phase 3	United States	National Cancer Institute	13 Mar 2023
Head and neck cancer metastatic	Phase 3	United States	National Cancer Institute	13 Mar 2023
Nasopharyngeal Carcinoma	Phase 3	United States	National Cancer Institute	13 Mar 2023
Nasopharyngeal Squamous Cell Carcinoma	Phase 3	United States	National Cancer Institute	13 Mar 2023
Oropharyngeal Neoplasms	Phase 3	United States	National Cancer Institute	13 Mar 2023
Recurrent Pharyngeal Squamous Cell Carcinoma	Phase 3	United States	National Cancer Institute	13 Mar 2023
Recurrent Squamous Cell Carcinoma of the Head and Neck	Phase 3	United States	National Cancer Institute	13 Mar 2023
Retinopathy of Prematurity	Phase 3	United States	National Eye Institute	27 Apr 2022
Retinopathy of Prematurity	Phase 3	Canada	National Eye Institute	27 Apr 2022
EGFR Mutation Lung Cancer	Phase 3	United States	National Cancer Institute	28 Dec 2020

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02839707 (CTgov)	Phase 2/3	Recurrent Ovarian Clear Cell Adenocarcinoma \| Recurrent Platinum-Resistant Primary Peritoneal Carcinoma \| Recurrent Primary Peritoneal Carcinoma ... View more	444	Computed Tomography+Pegylated Liposomal Doxorubicin Hydrochloride+atezolizumab (Arm I (PLD, Atezolizumab))	qkrcnuyaui = wheibhbsqd nojivdlpiv (hferbjcrij, zdfkqlkvbq - ytdeqgstve) View more	-	04 Mar 2025
				Computed Tomography+Pegylated Liposomal Doxorubicin Hydrochloride+atezolizumab+Bevacizumab (Arm II (PLD, Bevacizumab, Atezolizumab))	qkrcnuyaui = jsrdqzwpbj nojivdlpiv (hferbjcrij, emexondklo - veolmvmvox) View more
NCT03396926 (CTgov)	Phase 2	Microsatellite Stable Colorectal Carcinoma	44	Specimen collection+Pembrolizumab+Bevacizumab+Capecitabine (Safety Lead in Cohort: Treatment (Pembrolizumab, Bevacizumab, Capecitabine))	yfwrnaelva = fuvflwoxhx mzfsjhjbsl (udncmcvqgy, pefogswvnx - vqtcbuhkaw) View more	-	28 Feb 2025
				Specimen collection+Pembrolizumab+Bevacizumab+Capecitabine (Expansion Cohort: Treatment (Pembrolizumab, Bevacizumab, Capecitabine))	jiscbidvab(eklckwapcg) = zlbjjeajlg uoddsidaqq (uaahqsmgoq, yhksqhmdqb - pkemdqdqbv) View more
NCT01894061 (CTgov)	Phase 2	Gliosarcoma \| Recurrent Glioblastoma	25	NovoTTF-l00A+Bevacizumab	rkyogmmjqu = fvsspzgamg gexfwmadhs (gzwhevyxsv, xlffmxjjjf - ikqnuelxfp) View more	-	17 Feb 2025
NCT04487067 (AMETHISTA, Pubmed \| ESMO Open) Manual	Phase 3	Unresectable Hepatocellular Carcinoma First line	149	Atezolizumab + bevacizumab	kdczrrqnjp(bylzcdviqs) = bleeding/hemorrhages was 11.4% aumkzucjkw (htuiztwagd )	Positive	01 Feb 2025
NCT05359861 (ASCO_GI2025) Manual	Phase 2	Hepatocellular Carcinoma	30	Casdozo 10 mg/kg + Atezolizumab 1200 mg + Bevacizumab 15 mg/kg (RECIST1.1)	cljgjxavak(mpylwxqben) = uhusrtkrdr dswzfrwtks (tqwczhwwvt ) View more	Positive	23 Jan 2025
				Casdozo 10 mg/kg + Atezolizumab 1200 mgAtezolizumab 1200 mg + Bevacizumab 15 mg/kg (mRECIST)	ytlxpseoqq(nkgkshikhz) = djjebmddad wotowszxxu (zgudaujvlv ) View more
JPRN-jRCTs061180022 \| NCT02515734 (JACCRO CC-13, ASCO_GI2025) Manual	Phase 2	RAS Wild Type Colorectal Cancer RAS wild-type	359	m-FOLFOXIRI plus cetuximab	gxwqqgtrrt(lonzsebwdm) = epapfjwhue wbijseziak (ouulvhtsks ) View more	Positive	23 Jan 2025
				m-FOLFOXIRI plus bevacizumab	gxwqqgtrrt(lonzsebwdm) = yugpnjxhxj wbijseziak (ouulvhtsks ) View more
NCT06024252 (CHANCE 023, ASCO_GI2025) Manual	Not Applicable	Unresectable Hepatocellular Carcinoma Second line	293	Transarterial chemoembolization (TACE) + Atezolizumab + Bevacizumab	hfangvgmws(nlqyxspkto) = fjmljcryqh mxwirujrtn (iuwchbnguh ) View more	Positive	23 Jan 2025
NCT05776875 (CTgov)	Phase 2	Hepatocellular Carcinoma	3	Transarterial chemoembolization+Atezolizumab Injection+Bevacizumab	hogizdmriy = ddrnmurfiy psdtcauffk (zducqpgdzu, gzpqyqhdcf - ukuwediapo) View more	-	15 Jan 2025
NCT03133546 (BOOSTER, CTgov)	Phase 2	Non-small cell lung cancer stage IIIB \| Advanced Lung Non-Small Cell Carcinoma \| metastatic non-small cell lung cancer	155	Bevacizumab+Osimertinib (Osimertinib Plus Bevacizumab)	uamefiphfp(icjjynlzuw) = avqozaqptd dzaztloxar (gcivygnqvq, xeukfycwsj - iptchptjhj) View more	-	14 Jan 2025
				Osimertinib (Osimertinib Alone)	uamefiphfp(icjjynlzuw) = ykjjfpsboc dzaztloxar (gcivygnqvq, xxqmlnxcvc - yyizeuucoc) View more
NCT03452579 (NAVAL \| ATIM-40, CTgov)	Phase 2	Recurrent Glioblastoma	90	Nivolumab+Bevacizumab (Nivolumab + Standard Dose Bevacizumab)	gzwpdupkrt = btifbwkqhv rlbijgnweg (uzxcvgylsu, ipkekuyxpq - pdrxiozcfd) View more	-	13 Jan 2025
				Nivolumab+Low Dose Bevacizumab (Nivolumab + Low Dose Bevacizumab)	gzwpdupkrt = twaownlaoh rlbijgnweg (uzxcvgylsu, hdcmnzauhr - edhzxqezbj) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis